Skip to main content

Research Repository

Advanced Search

Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study

Nakafero, Georgina; Grainge, Matthew J; Card, Tim; Mallen, Christian D; Nguyen Van-Tam, Jonathan S; Abhishek, Abhishek; .

Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study Thumbnail


Authors

Dr TIM CARD tim.card@nottingham.ac.uk
CLINICAL ASSOCIATE PROFESSOR

Christian D Mallen

Jonathan S Nguyen Van-Tam

.



Abstract

Objective The uptake and safety of pneumococcal vaccination in people with immune mediated inflammatory diseases (IMIDs) is poorly understood. We investigated the UK wide pneumococcal vaccine uptake in adults with IMIDs and explored the association between vaccination and IMID flare. Methods Adults with IMIDs diagnosed on or before 01/09/2018, prescribed steroid-sparing drugs within the last 12 months and contributing data to the Clinical Practice Research Datalink Gold were included. Vaccine uptake was assessed using a cross-sectional study design. Self-controlled case series (SCCS) analysis investigated the association between pneumococcal vaccination and IMID flare. The SCCS observation period was up-to six-month before and after pneumococcal vaccination. This was partitioned into a 14-day pre-vaccination induction, 90-days post-vaccination exposed, and the remaining unexposed periods. Results We included 32 277 patients, 14 151 with RA, 13 631 with IBD, 3,804 with axial spondyloarthritis and 691 with SLE. Overall, 57% were vaccinated against pneumococcus. Vaccine uptake was lower in those younger than 45 years (32%), with IBD (42%), and without additional indication(s) for vaccination (46%). In the vaccine-safety study, data for 1,067, 935, and 451vaccinated patients with primary-care consultations for joint pain, AIRD flare and IBD flare respectively were included. Vaccination against pneumococcal pneumonia was not associated with primary-care consultations for joint pain, AIRD flare and IBD flare in the exposed period with incidence rate ratios (95% Confidence Interval) 0.95 (0.83–1.09), 1.05 (0.92–1.19), and 0.83 (0.65–1.06) respectively. Conclusion Uptake of pneumococcal vaccination in UK patients with IMIDs was suboptimal. Vaccination against pneumococcal disease was not associated with IMID flare.

Citation

Nakafero, G., Grainge, M. J., Card, T., Mallen, C. D., Nguyen Van-Tam, J. S., Abhishek, A., & . (2024). Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study. Rheumatology, Article keae160. https://doi.org/10.1093/rheumatology/keae160

Journal Article Type Article
Acceptance Date Mar 5, 2024
Online Publication Date Mar 13, 2024
Publication Date Mar 13, 2024
Deposit Date Mar 14, 2024
Publicly Available Date Mar 13, 2024
Journal Rheumatology
Electronic ISSN 1462-0324
Publisher Oxford University Press
Peer Reviewed Peer Reviewed
Article Number keae160
DOI https://doi.org/10.1093/rheumatology/keae160
Keywords Pneumococcal vaccination, rheumatoid arthritis, psoriatic arthritis, vaccine safety, vaccine uptake
Public URL https://nottingham-repository.worktribe.com/output/32464326
Publisher URL https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keae160/7628324